Black Diamond Therapeutics (BDTX) Return on Capital Employed (2020 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Return on Capital Employed came in at 43.15% in Q1 2026, down 4013.0% YoY from 1.1% in Q1 2025, and down 564.02% on a QoQ basis from 9.3% in Q4 2025.
Black Diamond Therapeutics (BDTX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 7 years of Return on Capital Employed data on file, last reported at 43.15% in Q1 2026.
- Quarterly Return on Capital Employed fell 4013.0% year-over-year to 43.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43.15% (down 4013.0% YoY) and the FY2025 annual result came in at 10.69%, up 7633.0% from the prior year.
- Return on Capital Employed retreated to 43.15% in Q1 2026, from 9.3% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 9.3% in Q4 2025 to a low of 75.17% in Q2 2023.
- A 5-year average of 46.87% and a median of 59.29% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed jumped 8112 bps — and 2026, when it slumped 4013 bps.
- Tracing BDTX's Return on Capital Employed over 5 years: stood at 60.64% in 2022, then rose by 2 bps to 59.29% in 2023, then declined by 21 bps to 71.82% in 2024, then soared by 113 bps to 9.3% in 2025, then sank by 564 bps to 43.15% in 2026.
- The last three Return on Capital Employed figures came in at 43.15% (Q1 2026), 9.3% (Q4 2025), and 8.09% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | -45.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.88% |
| Mar 31, 2026 | -43.15% |
| Dec 31, 2025 | 9.30% |
| Sep 30, 2025 | 8.09% |
| Jun 30, 2025 | 3.05% |
| Mar 31, 2025 | -3.02% |
| Dec 31, 2024 | -71.82% |
| Sep 30, 2024 | -66.07% |
| Jun 30, 2024 | -68.26% |
| Mar 31, 2024 | -63.69% |
| Dec 31, 2023 | -59.29% |
| Sep 30, 2023 | -66.73% |
| Jun 30, 2023 | -75.17% |
| Mar 31, 2023 | -66.66% |
| Dec 31, 2022 | -60.64% |
| Sep 30, 2022 | -57.61% |
| Jun 30, 2022 | -58.22% |
| Mar 31, 2022 | -56.90% |
| Dec 31, 2021 | -53.47% |
| Sep 30, 2021 | -48.69% |